Home › Funds › OAKTREE CAPITAL MANAGEMENT LP › CNMD
OAKTREE CAPITAL MANAGEMENT LP position in CNMD
CONMED CORP · Health Care
OAKTREE CAPITAL MANAGEMENT LP reported holding 53,645,000 shares of CNMD (CONMED CORP) in its Q2 2026 13F filing — a position valued at US$52.5M, representing 0.77% of its reported portfolio and ranking #30 among its reported holdings. OAKTREE CAPITAL MANAGEMENT LP has disclosed CNMD holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How OAKTREE CAPITAL MANAGEMENT LP's CNMD position evolved
OAKTREE CAPITAL MANAGEMENT LP first disclosed a stake in CNMD in Q3 2023 at 1,800,000 shares (US$1.7M). The position peaked in Q2 2026 at 53,645,000 shares, worth US$52.5M. Across 10 filings, OAKTREE CAPITAL MANAGEMENT LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 53,645,000 shares valued at US$52.5M — an increase of 17,456,000 shares quarter over quarter.. Notable position changes include a 1063% increase in Q4 2024 (shares fell 12% over the following quarter), a 120% increase in Q1 2025 (shares fell 14% over the following quarter), a 59% increase in Q2 2025 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.80M | $1.72M | New |
| Q4 2023 | 2.80M | $2.81M | Add |
| Q3 2024 | 681.00K | $633.45K | New |
| Q4 2024 | 7.92M | $7.37M | Add |
| Q1 2025 | 17.43M | $16.41M | Add |
| Q2 2025 | 27.70M | $26.32M | Add |
| Q3 2025 | 40.51M | $38.65M | Add |
| Q4 2025 | 40.32M | $38.71M | Hold |
| Q1 2026 | 36.19M | $35.12M | Reduce |
| Q2 2026 | 53.65M | $52.46M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CNMD and 13F data
CNMD (CONMED CORP) is a Health Care company. 13 other funds we track also report a position in CNMD — the largest reported positions include Invenomic Capital Management LP (US$27.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CNMD
- Invenomic Capital Management LP 842.16K sh · $27.56M · Q2 2026
More on OAKTREE CAPITAL MANAGEMENT LP
FAQ
How long has OAKTREE CAPITAL MANAGEMENT LP held CNMD?
OAKTREE CAPITAL MANAGEMENT LP has disclosed CNMD holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is OAKTREE CAPITAL MANAGEMENT LP's current position in CNMD?
As of Q2 2026, OAKTREE CAPITAL MANAGEMENT LP holds 53.65M shares of CNMD (CONMED CORP), valued at $52.46M, representing 0.77% of its reported portfolio and ranking #30.
Has OAKTREE CAPITAL MANAGEMENT LP been buying or selling CNMD?
In the latest 13F filing (Q2 2026), OAKTREE CAPITAL MANAGEMENT LP increased its position in CNMD. The position peaked in Q2 2026 at 53.65M shares.
Which other funds hold CNMD?
Other major institutional holders of CNMD include Invenomic Capital Management LP, among 13 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.